"In trying to take the road less traveled, Lilly will continue to supplement the output of its own labs with assets bought in at or near late-phase development. But Skovronsky also wants Lilly to come to the deal table sooner and buy in earlier-stage, higher-risk programs that feed its appetite for novel technologies."

https://www.fiercebiotech.com/biotech/lilly-s...d=48083647